
Genitourinary Cancers
Latest News

Adjuvant Treatment Advances Improve Outcomes in Kidney Cancer but Unmet Needs Persist
Video Series

Latest Videos
CME Content
More News

Ulka Vaishampayan, MD, FASCO, discusses different novel therapies in development for renal cell carcinoma.

Toni K. Choueiri, MD, discusses the potential clinical effects of data from the phase 3 LITESPARK-022 study.

Toni K. Choueiri, MD, discusses new data with adjuvant belzutifan plus pembrolizumab for the treatment of patients with clear cell RCC.

Toni K. Choueiri, MD, discusses safety data from the phase 3 LITESPARK-022 study in ccRCC.

Toni K. Choueiri, MD, discusses prior data that led to the initiation of the LITESPARK-022 trial in ccRCC.

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

In a recent Peer Exchange, experts discussed RCC management and treatment sequencing considerations ahead of ASCO GU 2026.

OncLive spoke with experts in the field of GU oncology to gain perspective on the biggest presentations from the 2026 Genitourinary Cancers Symposium.

The FDA has granted priority review to the sNDA seeking the approval of belzutifan plus pembrolizumab in ccRCC.

The addition of palbociclib to belzuitfan was not associated with improved responses in pretreated clear cell renal cell carcinoma.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

SBRT plus nivolumab and ipilimumab did not improve PFS vs the dual checkpoint inhibitor regimen alone in advanced RCC.

Toni K. Choueiri, MD, discusses data from the phase 3 LITESPARK-022 trial in ccRCC after nephrectomy.

Deep and durable responses were maintained with cabozantinib plus nivolumab in long-term follow-up of the CheckMate 9ER trial.

Pembrolizumab plus belzutifan reduced the risk of having a DFS event by 28% vs pembrolizumab alone in high-risk clear cell RCC.

Belzutifan plus lenvatinib significantly prolonged PFS and showed a trend toward improved OS vs cabozantinib in advanced ccRCC after anti–PD-L1 therapy.

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

Drs Armstrong and Tawagi highlight anticipated data from the upcoming 2026 Genitourinary Cancers Symposium in prostate, bladder, and kidney cancers.

Novel pembrolizumab-based combination regimens showed similar efficacy to the reference regimen in first-line ccRCC.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

Experts preview key bladder, kidney, and prostate cancer trials to watch at the 2026 Genitourinary Cancers Symposium.

The top 5 OncLive TV videos of the week cover insights in kidney cancer, myeloproliferative neoplasms, breast cancer, systemic mastocytosis, and pancreatic cancer.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.



























































